Abstract: The present invention provides systems and methods for powered video game playing cards, powered voter authentication cards, powered financial transaction cards, and methods for administering the use of each. The cards generally include a thin, flexible substrate and a battery disposed within the substrate. A dynamic token value generator and/or biometric sensor is disposed within the substrate and is powered by the battery. An electronic display is mounted on the substrate for displaying a token value generated by the dynamic token value generator. The token value is configured to be used in conjunction with a back-end token value secure identification system to provide access to secure electronic information or capabilities.

Abstract: Apparatuses and methods for packaging electronically powered cards are provided for maintaining electronically powered cards in a deactivated state. In an embodiment, a housing having a face panel and two side panels attached to the face panel at opposite sides is configured to provide an offset distance between an activation device on the card and the housing so that the activation device is prevented from being activated by a force exerted on the housing. Annular or circular devices can also be provided for establishing an offset distance between activation devices on the card and planar substrates.

Abstract: An electronic card comprises a thin, flexible substrate having electrical circuitry embedded therein. An activation device is disposed in the substrate and is configured to complete a circuit in response to a stimulus, such as light or sound. An output device is disposed in the substrate and is configured to produce an output, such as music or vibration, wherein the output device is activated upon the completion of the circuit by the activation device. A cavity is formed in an outer surface of the substrate and has electrical contacts at an inner portion thereof in electrical communication with the electrical circuitry. The cavity further comprises retaining means for replaceably retaining a battery in the cavity to enable the battery to provide power to the electrical circuitry, the activation device, and the output device. The retaining means allows a battery to be removed from the cavity and replaced with another battery.

Abstract: 2-Deoxygalactose and its analogs can be used to treat cancer and to improve patient outcome when administered in therapeutically effective doses alone or in combination with other anti-cancer drugs or with surgical resection or radiation therapy.

Abstract: Apparatuses and methods for packaging electronically powered cards are provided for maintaining electronically powered cards in a deactivated state. In an embodiment, a housing having a face panel and two side panels attached to the face panel at opposite sides is configured to provide an offset distance between an activation device on the card and the housing so that the activation device is prevented from being activated by a force exerted on the housing. Annular or circular devices can also be provided for establishing an offset distance between activation devices on the card and planar substrates.

Abstract: An electronic card comprises a thin, flexible substrate having electrical circuitry embedded therein. An activation device is disposed in the substrate and is configured to complete a circuit in response to a stimulus, such as light or sound. An output device is disposed in the substrate and is configured to produce an output, such as music or vibration, wherein the output device is activated upon the completion of the circuit by the activation device. A cavity is formed in an outer surface of the substrate and has electrical contacts at an inner portion thereof in electrical communication with the electrical circuitry. The cavity further comprises retaining means for replaceably retaining a battery in the cavity to enable the battery to provide power to the electrical circuitry, the activation device, and the output device. The retaining means allows a battery to be removed from the cavity and replaced with another battery.

Abstract: Compact powered systems are provided that include a substrate, a thin battery, an activation element, and an output device in electrical communication. The compact powered systems may be dynamic, powered print advertisements, product packaging, trading cards, printed ephemera or printed media that activate when subjected to an outside influence or stimulus. The output device is configured to, for example, display a number, graphic, or message, emit sound, cause movement or vibration, or transmit wireless signals in response to the stimulus.

Abstract: The present invention provides systems and methods for powered video game playing cards, powered voter authentication cards, powered financial transaction cards, and methods for administering the use of each. The cards generally include a thin, flexible substrate and a battery disposed within the substrate. A dynamic token value generator and/or biometric sensor is disposed within the substrate and is powered by the battery. An electronic display is mounted on the substrate for displaying a token value generated by the dynamic token value generator. The token value is configured to be used in conjunction with a back-end token value secure identification system to provide access to secure electronic information or capabilities.

Abstract: A method is provided for using ?2? subunit calcium channel modulators or other compounds that interact with the ?2? calcium channel subunit in combination with one or more compounds with smooth muscle modulatory effects to treat and/or alleviate the symptoms associated with painful and non-painful lower urinary tract disorders in normal and spinal cord injured patients. According to the present invention, ?2? subunit calcium channel modulators include GABA analogs (e.g. gabapentin and pregabalin), fused bicyclic or tricyclic amino acid analogs of gabapentin, and amino acid compounds. Compounds with smooth muscle modulatory effects include antimuscarinics, ?3 adrenergic agonists, spasmolytics, neurokinin receptor antagonists, bradykinin receptor antagonists, and nitric oxide donors.

Abstract: A packaging system for a consumable product held within a confined package. Plastic material is introduced within the confined packaging, preferably as a closure, seal or lining to the closed packaging. The plastic material has a surface that faces toward the consumable product within its packaging. The plastic material is fabricated from a composition that includes a plastic material and at least one scented material dissolved within that plastic material in a concentration in excess of its solubility at ambient temperature. The scented materials contained within the saturated plastic separates out of solution and migrates to the exposed surfaces of the plastic seal. The aroma volatiles are released from the plastic and fill the headspace of the packaging. These volatiles change the aromatic properties of the gases in the head space of the packaging.

Abstract: A method is provided for using Cav2.2 subunit calcium channel modulators to treat non-inflammatory gastrointestinal tract disorders.

Abstract: A method is provided for using ?2? subunit calcium channel modulators or other compounds that interact with the ?2? calcium channel subunit in combination with one or more compounds with smooth muscle modulatory effects to treat and/or alleviate the symptoms associated with painful and non-painful lower urinary tract disorders in normal and spinal cord injured patients. According to the present invention, ?2? subunit calcium channel modulators include GABA analogs (e.g. gabapentin and pregabalin), fused bicyclic or tricyclic amino acid analogs of gabapentin, and amino acid compounds. Compounds with smooth muscle modulatory effects include antimuscarinics, ?3 adrenergic agonists, spasmolytics, neurokinin receptor antagonists, bradykinin receptor antagonists, and nitric oxide donors.

Abstract: A method is provided for using ?2? subunit calcium channel modulators or other compounds that interact with the ?2? calcium channel subunit in combination with one or, more compounds with smooth muscle modulatory effects to treat functional bowel disorders in patients in need of treatment. According to the present invention, ?2? subunit calcium channel modulators include GABA analogs including gabapentin and pregabalin, fused bicyclic or tricyclic amino acid analogs of gabapentin, and amino acid compounds. Compounds with smooth muscle modulatory effects include antimuscarinics, ?3 adrenergic agonists, spasmolytics, neurokinin receptor antagonists, bradykinin receptor antagonists, and nitric oxide donors.

Abstract: A method is provided for using ?2? subunit calcium channel modulators or other compounds that interact with the ?2? calcium channel subunit in combination with one or more compounds with smooth muscle modulatory effects to treat pain. According to the present invention, ?2? subunit calcium channel modulators include GABA analogs (e.g., gabapentin and pregabalin), fused bicyclic or tricyclic amino acid analogs of gabapentin, and amino acid compounds. Compounds with smooth muscle modulatory effects include antimuscarinics, ?3 adrenergic agonists, spasmolytics, neurokinin receptor antagonists, bradykinin receptor antagonists, and nitric oxide donors.

Abstract: A method is provided for using ?2? subunit calcium channel modulators or other compounds that interact with the ?2? calcium channel subunit in combination with one or more compounds with smooth muscle modulatory effects to treat and/or alleviate the symptoms associated with painful and non-painful lower urinary tract disorders in normal and spinal cord injured patients. According to the present invention, ?2? subunit calcium channel modulators include GABA analogs (e.g. gabapentin and pregabalin), fused bicyclic or tricyclic amino acid analogs of gabapentin, and amino acid compounds. Compounds with smooth muscle modulatory effects include antimuscarinics, ?3 adrenergic agonists, spasmolytics, neurokinin receptor antagonists, bradykinin receptor antagonists, and nitric oxide donors.

Abstract: The invention relates to a method of treating at least one symptom of irritable bowel syndrome selected from the group consisting of: abnormal stool frequency, abnormal stool form, abnormal stool passage, passage of mucus and feeling of abdominal distension in a subject in need thereof. In certain embodiments, the pain and discomfort associated with irritable bowel syndrome is also reduced. The method comprises administering to a subject in need of treatment a therapeutically effective amount of a compound that has 5-HT3 receptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity.

Abstract: A computer-based system permitting a visually impaired user to interact with tactile graphic-based interactive software applications is provided. The system includes a host computer having a data processor and a drive for running the interactive software applications and a pressure sensitive work pad. The work pad has X and Y pressure sensitive members disposed in a grid array for providing unique location output signals corresponding to each different location on the grid array. The work pad is operatively connected to the host computer and an overlay comprising a sheet is placed over an upper surface of the work pad. The overlay having a work space which bears tactile indicia which corresponds to a selected one of the interactive software applications and also includes a tactile graphical user interface (TGUI) formed thereon. The TGUI has a plurality of tactile control members which generate location output signals when pressed.